BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 17325736)

  • 1. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
    Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
    Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis.
    Dervieux T; Furst D; Lein DO; Capps R; Smith K; Walsh M; Kremer J
    Arthritis Rheum; 2004 Sep; 50(9):2766-74. PubMed ID: 15457444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis.
    Berkun Y; Abou Atta I; Rubinow A; Orbach H; Levartovsky D; Aamar S; Arbel O; Dresner-Pollak R; Friedman G; Ben-Yehuda A
    J Rheumatol; 2007 Aug; 34(8):1664-9. PubMed ID: 17611986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.
    Wessels JA; de Vries-Bouwstra JK; Heijmans BT; Slagboom PE; Goekoop-Ruiterman YP; Allaart CF; Kerstens PJ; van Zeben D; Breedveld FC; Dijkmans BA; Huizinga TW; Guchelaar HJ
    Arthritis Rheum; 2006 Apr; 54(4):1087-95. PubMed ID: 16572443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis.
    Li X; Hu M; Li W; Gu L; Chen M; Ding H; Vanarsa K; Du Y
    Int Immunopharmacol; 2016 Sep; 38():8-15. PubMed ID: 27233001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced folate carrier-1 80G > A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis.
    Muralidharan N; Mariaselvam CM; Mithun CB; Negi VS
    Clin Rheumatol; 2016 Apr; 35(4):879-85. PubMed ID: 25771854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study.
    Dervieux T; Furst D; Lein DO; Capps R; Smith K; Caldwell J; Kremer J
    Ann Rheum Dis; 2005 Aug; 64(8):1180-5. PubMed ID: 15677700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
    Kumagai K; Hiyama K; Oyama T; Maeda H; Kohno N
    Int J Mol Med; 2003 May; 11(5):593-600. PubMed ID: 12684695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis.
    Jansen G; van der Heijden J; Oerlemans R; Lems WF; Ifergan I; Scheper RJ; Assaraf YG; Dijkmans BA
    Arthritis Rheum; 2004 Jul; 50(7):2130-9. PubMed ID: 15248210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients.
    Samara SA; Irshaid YM; Mustafa KN
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):746-55. PubMed ID: 25074866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.
    Whittle SL; Hughes RA
    Rheumatology (Oxford); 2004 Mar; 43(3):267-71. PubMed ID: 14963199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis.
    Rizzo R; Rubini M; Govoni M; Padovan M; Melchiorri L; Stignani M; Carturan S; Ferretti S; Trotta F; Baricordi OR
    Pharmacogenet Genomics; 2006 Sep; 16(9):615-23. PubMed ID: 16906016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients.
    Lima A; Bernardes M; Sousa H; Azevedo R; Costa L; Ventura F; Seabra V; Medeiros R
    Pharmacogenomics; 2014 Apr; 15(6):807-20. PubMed ID: 24350725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis.
    Wolf J; Stranzl T; Filipits M; Pohl G; Pirker R; Leeb B; Smolen JS
    Ann Rheum Dis; 2005 Apr; 64(4):564-8. PubMed ID: 15345497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis.
    Dervieux T; Wessels JA; van der Straaten T; Penrod N; Moore JH; Guchelaar HJ; Kremer JM
    Pharmacogenet Genomics; 2009 Dec; 19(12):935-44. PubMed ID: 19858780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis.
    Wessels JA; Kooloos WM; De Jonge R; De Vries-Bouwstra JK; Allaart CF; Linssen A; Collee G; De Sonnaville P; Lindemans J; Huizinga TW; Guchelaar HJ
    Arthritis Rheum; 2006 Sep; 54(9):2830-9. PubMed ID: 16947783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperhomocysteinemia in rheumatoid arthritis: influence of methotrexate treatment and folic acid supplementation.
    Jensen OK; Rasmussen C; Mollerup F; Christensen PB; Hansen H; Ekelund S; Thulstrup AM
    J Rheumatol; 2002 Aug; 29(8):1615-8. PubMed ID: 12180718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTPN22 1858C>T polymorphism is strongly associated with rheumatoid arthritis but not with a response to methotrexate therapy.
    Majorczyk E; Pawlik A; Kuśnierczyk P
    Int Immunopharmacol; 2010 Dec; 10(12):1626-9. PubMed ID: 20888443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.